Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipistad
- Development stage
- Phase 3
- Lead developer
- Pirkanmaan hyvinvointialue
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Lipistad is a liposomal formulation of disulfiram, an aldehyde dehydrogenase (ALDH) inhibitor traditionally used to treat alcohol use disorder, now being repurposed for the treatment of metastatic cancers. Developed by researchers at Pirkanmaan hyvinvointialue in Finland, Lipistad is designed to improve the pharmacokinetic profile and stability of disulfiram, which is otherwise rapidly degraded in the bloodstream. The drug's anti-cancer activity is primarily mediated through its metabolite, diethyldithiocarbamate (DDC), which complexes with copper ions to form Cu-DDC. This complex specifically targets and inhibits the NPL4 protein (encoded by the NPLOC4 gene), a critical adaptor for the p97/VCP segregase that is essential for the turnover of polyubiquitinated proteins. Inhibition of the NPL4-p97 pathway leads to proteotoxic stress, accumulation of unfolded proteins, and subsequent apoptosis, particularly in cancer stem cells that overexpress ALDH. Lipistad is currently undergoing Phase 1 clinical evaluation for patients with metastatic breast, ovarian, prostate, and kidney cancers.
- Brand names
- Lipistad
- Other names
- liposomal disulfiram
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)NPL4 (Nuclear protein localization protein 4 cofactor–valosin-containing protein segregase complex)
Beyond the preview
Go deeper on Lipistad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipistad.